Navigation Links
Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
Date:9/22/2008

NEW HAVEN, Conn., Sept. 22 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) announced today that it had entered into an agreement with the Institut Paoli-Calmettes in Marseille, France to conduct a multi-center Phase I/II clinical trial of laromustine (Cloretazine (VNP40101M)) with remission-induction therapy in patients aged 18-60 with previously untreated acute myelogenous leukemia (AML) and a poor prognosis based on their cytogenetic profile.

The Institut Paoli-Calmettes will be leading the study for the French cooperative group GOELAMS (Groupe Ouest Est d'Etude des Leucemies et Autres Maladies du Sang).

Alan Kessman, Chief Executive Officer, commented, "We are pleased to be working with the Paoli-Calmettes Institute and GOELAMS on this clinical study to further evaluate the role that Cloretazine can play in frontline AML therapy. This study will provide important information on the combination of Cloretazine and induction therapy in patients with unfavorable cytogenetics that need new treatment options."

Dr. Norbert Vey, Head of the Leukemia Service of the Institut Paoli-Calmettes and Chief Investigator, said, "AML with unfavorable cytogenetics is a very serious form of leukemia from which few patients can be cured currently. The objective of our study is to improve the complete remission rate in these patients with the addition of Cloretazine to a conventional induction regimen."

The trial will be conducted in two parts. In Phase I, the objective is to determine the dose of Cloretazine in combination with daunorubicin and cytarabine. Phase II will determine the complete remission (CR) rate of the combination in AML patients with an unfavorable prognosis based on their cytogenetic profile. Secondary objectives will be to evaluate the tolerance and toxicities of the combination therapy, as well as progression-free survival and overall survival. Patients will be stratified according to age (less tha
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...ire-FirstCall/--Abaxis,Inc.(Nasdaq: ABAX ),amedica...lysissystems,announcedtodaythatClintSeverson,chair...nualPiperJaffrayHealthCareConferenceonWednesday,De...theNewYorkPalaceHotelinNewYorkCity. ,, AboutAb...ortablebloodanalysissystemsforuseinanyveterinaryor...
(Date:11/25/2009)...ortlinker.comannouncesthatanewmarketresearchreport...GlobalTrends ,, http://www.reportlinker.com/..., Widespreadavailabilityofgenericdrugs,emergenceo...cceleratedthepaceofgrowthinthepainmanagementmarket...etoshapedemandforservices,drugsanddevices.Themarke...
(Date:11/24/2009)...Asia/--ChindexInternational,Inc.,("Chindex")(Nasda...tern,healthcareproductsandservicesinthePeople,sRep...ndthe21stAnnualPiperJaffray,"Unplugged"HealthCareC...laceHotel. , Managementiscurrentlyscheduledto...done-on-onemeetingsthroughouttheday.Awebcast,ofthe...
Breaking Medicine Technology:Reportlinker Adds Pain Management - Global Trends 2Reportlinker Adds Pain Management - Global Trends 3Reportlinker Adds Pain Management - Global Trends 4Reportlinker Adds Pain Management - Global Trends 5Chindex International to Present at Piper Jaffray Health Care Conference 2CMHS 28dba Hybrid Energy Holdings 29 changes name of corporation and prepares to file for ticker symbol change with FINRA 58135 1CMHS 28dba Hybrid Energy Holdings 29 changes name of corporation and prepares to file for ticker symbol change with FINRA 58135 2Bubble Trouble Team Hits the Lab for Good Hygiene 58133 1Bubble Trouble Team Hits the Lab for Good Hygiene 58133 2Bubble Trouble Team Hits the Lab for Good Hygiene 58133 3Bubble Trouble Team Hits the Lab for Good Hygiene 58133 4MedShape Solutions Inc Announces First FDA cleared Shape Memory PEEK Device 3B Closing of 2410M Equity Offering 14230 1MedShape Solutions Inc Announces First FDA cleared Shape Memory PEEK Device 3B Closing of 2410M Equity Offering 14230 2
...Pain Conditions; Compound Currently in Phase...A, Calif., Aug. 27 TorreyPines,Therapeutics, Inc....iated a,Phase I multiple dose clinical trial to ev...cs of tezampanel given as a subcutaneous injection...for four consecutive days.,Tezampanel, an AMPA/kai...
... Brings Proprietary Artificial, Intelligence-Base...s to Upstream- -In...ivity Against, Devastating Parasitic Diseases Af... B.C., Aug. 27 Upstream Biosciences,Inc. (OTC Bul...d the,acquisition of Pacific Pharma Technologies I...
Other Medicine Technology:TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel 2TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel 3TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel 4Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases 2Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases 3Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases 4Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases 5Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases 6Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases 7
(Date:11/26/2009)...munications announces a highly effective and uncon...uggling to make an economic recovery. , ...ars is the type of challenge that could send ailin...o Dr. David Benton, business growth expert and aut...ndash; The Rfactor Intensive . “Fear is o...
(Date:11/25/2009)...wire/--TheBartleHallConventionCenterwilltemporaril...henKansasCityhoststhelatestinaseriesofmassivefreec...nthasthepotentialtobethebiggestoneyet,becauseitwil...aysinsteadofoveraweekend,"SheriWood,executivedirec...eNationalAssociationofFreeClinics(NAFC). ,, Atp...
(Date:11/25/2009)...entinelleMedicalInc.,aleadingmanufacturerofbreastM...iteofnewleadingedgeclinicalapplicationsonitsAegis(...logicalSocietyofNorthAmerica(RSNA)annualmeetinginC...cationsleveragetheuniquehighqualityimagesgenerated...multipleimagingmodalitiesformulti-parametricassess...
(Date:11/25/2009)...-USNewswire/--TheBlackAIDSInstituterecentlyheldBoa...pfor2010. ,, ThenewBoardMembersareahighlydivers...inance,governmenthealthprograms,editorial,andbusin...eofpersonalbackgroundsincludingbothheterosexualand...drepresentingmultipleagegroups. ,, (Photo: http...
(Date:11/25/2009)...cancer who were treated with cisplatin-based chemo...urological side effects and Raynaud-like phenomena... according to a new study published online Novembe...ute . , Marianne Brydy, M.D., of the Department ...gen, Norway, and colleagues conducted a cross-sect...
Breaking Medicine News(10 mins):Health News:Pharmacist Injects Cure for Ailing Businesses 2Health News:Kansas City Prepares for Largest Free Health Clinic 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Black AIDS Institute Announces 2010 Board Election Results 2
...m the breast bone to the groin , , PITTSBURGH, Fe...tricians and nurses at Children,s Hospital of Pitt...d twins during a 24-hour procedure. , , The 2-yea...ded 24 hours later. The girls currently are recove...
...Inc. (NYSE:MDT) and Envisionier Medical Technologi...d an agreement that grants exclusive rights for US...tem to the ENT (ear, nose, and throat) division of...erated, palm-held endoscopic imaging system for th...
...ertility specialists marks its 25th anniversary wi...ged by economic downturn , , SAN RAMON, Calif., F... one of the nation,s first fertility clinics is ex...imate nationwide. , , Established just two years ...
...ia-FirstCall/ -- China-Biotics, Inc.,(Nasdaq: CH...hinese firm,specializing in the manufacture, resea...obiotics products, today announced its financial r...ear-over-year to $15.8 million, -- Gross profit...
...edrest Fitness was released offering pregnant wo...he first of its kind, Bedrest Fitness is a ser...r restricted activity can perform to help maintain...s has been well received by both clinicians and ...
... improvements remains unclear , , MONDAY, ...he effects of genetics on blood pressure in humans... levels of salt in the body with high blood pressu..." said Dr. Christopher Newton-Cheh, assistant prof...
Other Medicine News:Health News:Conjoined Twins Separated by Surgical Team at Children's Hospital of Pittsburgh of UPMC During Complex, 24-Hour Procedure 2Health News:Envisionier and Medtronic Announce Agreement 2Health News:Bay Area Fertility Clinic to Offer Special Help During Recession 2Health News:China-Biotics, Inc. Reports Third Quarter 2009 Financial Results 2Health News:China-Biotics, Inc. Reports Third Quarter 2009 Financial Results 3Health News:China-Biotics, Inc. Reports Third Quarter 2009 Financial Results 4Health News:China-Biotics, Inc. Reports Third Quarter 2009 Financial Results 5Health News:China-Biotics, Inc. Reports Third Quarter 2009 Financial Results 6Health News:China-Biotics, Inc. Reports Third Quarter 2009 Financial Results 7Health News:China-Biotics, Inc. Reports Third Quarter 2009 Financial Results 8Health News:China-Biotics, Inc. Reports Third Quarter 2009 Financial Results 9Health News:China-Biotics, Inc. Reports Third Quarter 2009 Financial Results 10Health News:China-Biotics, Inc. Reports Third Quarter 2009 Financial Results 11Health News:China-Biotics, Inc. Reports Third Quarter 2009 Financial Results 12Health News:Spanish Exercise DVD Helps Latinas Reduce Risk of Preterm Labor 2Health News:Genes That Control Body's Salt Levels Are Identified 2Health News:Genes That Control Body's Salt Levels Are Identified 3
Lucas
Kevorkian Collector Endocervical Curette
Kevorkian Endocervical Curette
Micro Decker Rongeur
Medicine Products: